Free Trial
NASDAQ:RCEL

Avita Medical (RCEL) Stock Price, News & Analysis

Avita Medical logo
$15.63 -0.57 (-3.52%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$15.62 -0.01 (-0.03%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Avita Medical Stock (NASDAQ:RCEL)

Advanced

Key Stats

Today's Range
$15.32
▼
$16.11
50-Day Range
$9.86
▼
$17.65
52-Week Range
$3.22
▼
$18.43
Volume
497,276 shs
Average Volume
575,372 shs
Market Capitalization
$491.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.60
Consensus Rating
Moderate Buy

Company Overview

AVITA Medical is a regenerative medicine company focused on treatments for skin restoration. Its flagship technology, the RECELL System, enables clinicians to use a small sample of a patient’s healthy skin to prepare a suspension of skin cells for application to wounds.

The company’s RECELL products are used in the treatment of burns and certain other skin injuries, including full-thickness skin defects. The approach is intended to support wound coverage while reducing the amount of donor skin needed compared with conventional skin-grafting procedures.

AVITA Medical has Australian roots and has expanded its operations internationally, with a focus on markets including the United States and Australia. Its products are used in clinical settings such as hospitals and burn centers.

AI Generated. May Contain Errors.

Avita Medical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

RCEL MarketRank™: 
1.74554273728 of 5 stars

Avita Medical scored higher than 35% of companies evaluated by MarketBeat, and ranked 769th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Avita Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside/Downside

    The consensus price target for Avita Medical is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Avita Medical has only been the subject of 4 research reports in the past 90 days.

  • Read more about Avita Medical's stock forecast and price target.
  • Earnings Growth

    Earnings for Avita Medical are expected to grow in the coming year, from ($0.94) to ($0.38) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Avita Medical is -13.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Avita Medical is -13.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    9.14% of the float of Avita Medical has been sold short.
  • Short Interest Ratio / Days to Cover

    Avita Medical has a short interest ratio ("days to cover") of 6.12.
  • Change versus previous month

    Short interest in Avita Medical has recently decreased by 1.02%, indicating that investor sentiment is improving.
  • Dividend Yield

    Avita Medical does not currently pay a dividend.

  • Dividend Growth

    Avita Medical does not have a long track record of dividend growth.

  • News Sentiment

    Avita Medical has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Avita Medical this week, compared to 3 articles on an average week.
  • Search Interest

    4 people have searched for RCEL on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Avita Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Avita Medical insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    2.24% of the stock of Avita Medical is held by insiders.

  • Percentage Held by Institutions

    27.66% of the stock of Avita Medical is held by institutions.

  • Read more about Avita Medical's insider trading history.
Receive RCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avita Medical and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RCEL Stock News Headlines

Avita Medical (NASDAQ:RCEL) Stock Lifted to Buy by Wall Street Zen
Critical Survey: QuidelOrtho (NASDAQ:QDEL) and Avita Medical (NASDAQ:RCEL)
The warning signs most investors see too late
Dr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.tc pixel
The Bet Behind AVITA Medical's 393% Run
Avita Medical (NASDAQ:RCEL) Price Target Raised to $21.00
AVITA Medical to Host Investor Webinar Briefing
See More Headlines

RCEL Stock Analysis - Frequently Asked Questions

Avita Medical's stock was trading at $3.45 on January 1st, 2026. Since then, RCEL stock has increased by 353.0% and is now trading at $15.63.

Avita Medical Inc. (NASDAQ:RCEL) announced its quarterly earnings results on Thursday, November, 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04. The company earned $26.11 million during the quarter, compared to analyst estimates of $22.35 million.
Read the conference call transcript
.

Top institutional shareholders of Avita Medical include Marshall Wace LLP (2.23%), State Street Corp (0.48%), Russell Investments Group Ltd. (0.13%) and Jefferies Financial Group Inc. (0.12%). Insiders that own company stock include David D O'toole, David D O'toole, Joseph Fralin Woody, Robert Mcnamara, Suzanne Crowe, Jeremy Curnock Cook and James Corbett.
View institutional ownership trends
.

Shares of RCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Avita Medical investors own include NVIDIA (NVDA), PayPal (PYPL), Intel (INTC), Micron Technology (MU), Netflix (NFLX), Bristol Myers Squibb (BMY) and Salesforce (CRM).

Company Calendar

Last Earnings
11/05/2026
Today
11/13/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:RCEL
CIK
1762303
Fax
N/A
Employees
226
Year Founded
1992

Price Target and Rating

High Price Target
$22.00
Low Price Target
$10.00
Potential Upside/Downside
+6.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.18)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$48.59 million
Net Margins
-42.65%
Pretax Margin
-42.57%
Return on Equity
N/A
Return on Assets
-71.34%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.20
Quick Ratio
0.99

Sales & Book Value

Annual Sales
$71.61 million
Price / Sales
6.86
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.99) per share
Price / Book
-15.79

Miscellaneous

Outstanding Shares
31,420,000
Free Float
30,716,000
Market Cap
$491.09 million
Optionable
Optionable
Beta
2.03

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:RCEL) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners